Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: ASAIO J. 2018 May-Jun;64(3):287–294. doi: 10.1097/MAT.0000000000000684

Figure 2.

Figure 2

Forest plot of infection rates for the HeartMate II compared with the HeartWare HVAD: data from Haglund et al45 (all types of infections, including driveline, sternal wound, and non-LVAD infections); Majure et al9 (rehospitalizations due to LVAD infections); and Sabashnikov et al8 (percutaneous site infections treated only with antimicrobial agents); and the Evaheart: data from Matsumoto et al10 (freedom-from-exit-site infection at 1 year [major endpoint], presented as number of patients with at least 1 exit-site infection in 1 year). Pooled estimates were not significant, likely because of the high degree of heterogeneity in the studies.